论文部分内容阅读
目的观察卡维地洛对尿毒症心肌病患者心、肾功能及心脏结构的影响。方法100例患者随机分为两组,每组50例。一组予以常规治疗(对照组),另一组加用卡维地洛(治疗组)。观察SV、EF、CO、LVEDD、IVST、LVPWT、LVM、LVMI、BUN、Scr、Ccr的变化。结果两组SV、EF、CO、LVEDD、IVST、LVPWT、LVM、LVMI均有所改善(P<0.01)或(P<0.001)。治疗组改善高于对照组(P<0.05),Ccr有增加趋势(P>0.05),BUN、Scr有下降趋势(P>0.05)。结论卡维地洛能改善尿毒症心肌病患者的心功能及结构,对肾功能也有改善趋势。
Objective To observe the effects of carvedilol on cardiac and renal function and cardiac structure in patients with uremic cardiomyopathy. Methods 100 patients were randomly divided into two groups, 50 cases in each group. One group was treated routinely (control group) and the other group was given carvedilol (treatment group). The changes of SV, EF, CO, LVEDD, IVST, LVPWT, LVM, LVMI, BUN, Scr and Ccr were observed. Results The SV, EF, CO, LVEDD, IVST, LVPWT, LVM and LVMI were improved in both groups (P <0.01) or (P <0.001). The treatment group improved more than the control group (P <0.05), Ccr increased (P> 0.05), BUN, Scr decreased (P> 0.05). Conclusion Carvedilol can improve the cardiac function and structure of patients with uremic cardiomyopathy, but also improve renal function.